Literature DB >> 33207944

Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.

Karen E Skinner1, Amin Haiderali2, Min Huang2, Lee S Schwartzberg3.   

Abstract

Aim: This study examined treatment patterns and effectiveness outcomes of patients with metastatic triple-negative breast cancer (mTNBC) from US community oncology centers. Materials & methods: Eligible patients were females, aged ≥18 years, diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Kaplan-Meier and Cox regression methods were used.
Results: Sample comprised 608 patients with average age of 57.5 years and 505/608 patients (83.1%) received systemic treatment. Overall survival (OS) from first-line treatment found that African-American patients had shorter OS than White (9.3 vs 13.7 months; hazard ratio: 1.35; p = 0.006).
Conclusion: More than 15% of women with mTNBC were not treated, indicating a high unmet need. Overall prognosis remains poor, which highlights the opportunity for newer therapies to improve progression-free survival and OS.

Entities:  

Keywords:  African–American patients; community oncology; metastatic triple-negative breast cancer; overall survival; progression-free survival; treatment patterns

Year:  2020        PMID: 33207944     DOI: 10.2217/fon-2020-1021

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  5 in total

1.  Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices.

Authors:  Ruoding Tan; Lourenia Cassoli; Ying Yan; Vincent Shen; Bann-Mo Day; Edith P Mitchell
Journal:  Front Public Health       Date:  2022-05-24

2.  Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report.

Authors:  Georges Azzi; Shifra Krinshpun; Antony Tin; Minu Maninder; Allyson Koyen Malashevich; Meenakshi Malhotra; Ruben Ruiz Vega; Paul R Billings; Angel Rodriguez; Alexey Aleshin
Journal:  Case Rep Oncol       Date:  2022-05-02

3.  Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.

Authors:  Ju-Yi Hsu; Chee-Jen Chang; Jur-Shan Cheng
Journal:  Sci Rep       Date:  2022-01-14       Impact factor: 4.379

4.  Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis.

Authors:  Xuchen Huang; Xuhua Hu; Tongbo Yi
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

5.  IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer.

Authors:  Nicholas R Hum; Aimy Sebastian; Kelly A Martin; Naiomy D Rios-Arce; Sean F Gilmore; David M Gravano; Elizabeth K Wheeler; Matthew A Coleman; Gabriela G Loots
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.